Arrowhead Pharmaceuticals (ARWR) total liabilities
Arrowhead Pharmaceuticals (ARWR) had total liabilities of $1.69B at the end of fiscal 2026 (September 30, 2026). That is 91.4% higher than the $881.88M of fiscal 2025. Figures as of 19 Nov 2026, 00:32 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Total liabilities, fiscal 2026
- $1.69B
- Change on fiscal 2025
- +91.4%
- Highest on record
- $1.69Bfiscal 2026
- Lowest on record
- $478.39Mfiscal 2023
- Fiscal years on record
- 42023–2026
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Arrowhead Pharmaceuticals total liabilities, in more detail
Across the 4 fiscal years on record (2023–2026), the highest was $1.69B in fiscal 2026 and the lowest $478.39M in fiscal 2023.
Total liabilities by fiscal year
Arrowhead Pharmaceuticals total liabilities, year by year
| Fiscal year | Total liabilities | Change | Year ended |
|---|---|---|---|
| 2026 | $1.69B | 91.4% up | |
| 2025 | $881.88M | 7.0% down | |
| 2024 | $948.74M | 98.3% up | |
| 2023 | $478.39M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.
How to read it
It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.
Total liabilities at health care companies of similar size
| Company | Total liabilities | Fiscal year |
|---|---|---|
| Axsome Therapeutics AXSM | $601.51M | 2025 |
| Chemed CHE | $558.78M | 2025 |
| Oruka Therapeutics ORKA | $16.69M | 2025 |
| Arrowhead Pharmaceuticals ARWR | $1.69B | 2026 |
| MSA Safety MSA | $1.19B | 2025 |
| CG Oncology CGON | $38.99M | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Arrowhead Pharmaceuticals, figure by figure
- Arrowhead Pharmaceuticals market cap
- Arrowhead Pharmaceuticals revenue
- Arrowhead Pharmaceuticals earnings
- Arrowhead Pharmaceuticals earnings per share (EPS)
- Arrowhead Pharmaceuticals P/E ratio
- Arrowhead Pharmaceuticals P/S ratio
- Arrowhead Pharmaceuticals P/B ratio
- Arrowhead Pharmaceuticals free cash flow
- Arrowhead Pharmaceuticals operating margin
- Arrowhead Pharmaceuticals dividend
- Arrowhead Pharmaceuticals shares outstanding
- Arrowhead Pharmaceuticals total debt
- Arrowhead Pharmaceuticals cash on hand
- Arrowhead Pharmaceuticals total assets
- Arrowhead Pharmaceuticals net assets (shareholders' equity)
- Arrowhead Pharmaceuticals return on equity (ROE)
- Arrowhead Pharmaceuticals return on invested capital (ROIC)
Arrowhead Pharmaceuticals (ARWR) overview: price, valuation and scorecardAll health care companies by market value
Arrowhead Pharmaceuticals total liabilities: questions and answers
How large are Arrowhead Pharmaceuticals's total liabilities?
Arrowhead Pharmaceuticals (ARWR) had total liabilities of $1.69B at the end of fiscal 2026 (September 30, 2026). That is 91.4% higher than the $881.88M of fiscal 2025.
What are the highest and lowest total liabilities figures on record for Arrowhead Pharmaceuticals?
Across the 4 fiscal years on record (2023–2026), the highest was $1.69B in fiscal 2026 and the lowest $478.39M in fiscal 2023.
How is Arrowhead Pharmaceuticals's total liabilities calculated?
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Arrowhead Pharmaceuticals it is on record here for 4 fiscal years, 2023 to 2026.
Fiscal years are named for the calendar year they end in.
Learn: total liabilities
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Arrowhead Pharmaceuticals (ARWR) total liabilities”, data as of 19 November 2026. https://funkfolio.com/stock/ARWR/total-liabilities
Underlying data: the company's filings with the SEC and Yahoo Finance.